Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

被引:50
作者
Frumovitz, Michael
Sood, Anil K.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词
vascular endothelial growth factor (VEGF); angiogenesis; gynecologic cancer;
D O I
10.1016/j.ygyno.2006.10.062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis, which is required for tumor growth and metastasis. In this article, a review of the functional and biological roles of the VEGF pathway in driving angiogenesis and growth of gynecologic malignancies was performed. Based on the biological functions of VEGF, multiple approaches for targeting the VEGF/VEGF-receptor complex have been developed and many of these have demonstrated substantial activity in preclinical models. These promising data have led to rapid clinical development of VEGF-targeted agents. Therefore, we also assessed the status of VEGF-targeted therapies and associated toxicities in gynecologic malignancies. However, many questions remain related to optimal dosing, sequencing of therapies, management of toxicities, appropriate patient selection, and assessment of response, which will require further studies. Nevertheless, VEGF-targeted therapies offer hope for improving the outcome of cancer patients. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:768 / 778
页数:11
相关论文
共 81 条
[21]  
Garcia AA, 2005, J CLIN ONCOL, V23, p455S
[22]   VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism [J].
Gerber, HP ;
Malik, AK ;
Solar, GP ;
Sherman, D ;
Liang, XH ;
Meng, G ;
Hong, K ;
Marsters, JC ;
Ferrara, N .
NATURE, 2002, 417 (6892) :954-958
[23]   Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix [J].
Gombos, Z ;
Xu, XW ;
Chu, CS ;
Zhang, PJ ;
Acs, G .
CLINICAL CANCER RESEARCH, 2005, 11 (23) :8364-8371
[24]   Managing patients treated with bevacizumab combination therapy [J].
Gordon, MS ;
Cunningham, D .
ONCOLOGY, 2005, 69 :25-33
[25]   Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy [J].
Halder, Jyotsnabaran ;
Kamat, Aparna A. ;
Landen, Charles N., Jr. ;
Han, Liz Y. ;
Lutgendorf, Susan K. ;
Lin, Yvonne G. ;
Merritt, William M. ;
Jennings, Nicholas B. ;
Chavez-Reyes, Arturo ;
Coleman, Robert L. ;
Gershenson, David M. ;
Schmandt, Rosemarie ;
Cole, Steven W. ;
Lopez-Berestein, Gabriel ;
Sood, Anil K. .
CLINICAL CANCER RESEARCH, 2006, 12 (16) :4916-4924
[26]   Antiangiogenic and antitumor effects of Src inhibition in ovarian carcinoma [J].
Han, Liz Y. ;
Landen, Charles N. ;
Trevino, Jose G. ;
Halder, Jyotsnabaran ;
Lin, Yvonne G. ;
Kamat, Aparna A. ;
Kim, Tae-Jin ;
Merritt, William M. ;
Coleman, Robert L. ;
Gershenson, David M. ;
Shakespeare, William C. ;
Wang, Yihan ;
Sundaramoorth, Raji ;
Metcalf, Chester A., III ;
Dalgarno, David C. ;
Sawyer, Tomi K. ;
Gallick, Gary E. ;
Sood, Anil K. .
CANCER RESEARCH, 2006, 66 (17) :8633-8639
[27]  
HEFLER LA, 2006, GYNECOL ONCOL
[28]   Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma [J].
Hendrix, MJC ;
Seftor, EA ;
Hess, AR ;
Seftor, REB .
NATURE REVIEWS CANCER, 2003, 3 (06) :411-421
[29]   Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis [J].
Hicklin, DJ ;
Ellis, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :1011-1027
[30]   Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma [J].
Hirai, M ;
Nakagawara, A ;
Oosaki, T ;
Hayashi, Y ;
Hirono, M ;
Yoshihara, T .
GYNECOLOGIC ONCOLOGY, 2001, 80 (02) :181-188